Apellis Pharmaceuticals, Inc. has achieved a significant milestone with the FDA approval of Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 and above. These rare kidney diseases affect an estimated 5,000 individuals in the United States. The approval of Empaveli represents a pivotal moment in the treatment of these conditions, offering a highly effective therapy to reduce proteinuria and potentially prevent disease progression to kidney failure.
The phase 3 VALIANT study demonstrated impressive results with Empaveli, showing a 68% reduction in proteinuria, stabilization of kidney function, and significant clearance of C3 deposits compared to placebo. This groundbreaking treatment has the potential to transform the lives of patients with C3G and primary IC-MPGN, who have had limited treatment options until now. Apellis Pharmaceuticals is dedicated to improving patient access and support through programs like ApellisAssist, offering comprehensive assistance throughout the treatment journey. With a well-established safety profile and proven efficacy, Empaveli is set to make a significant impact on the lives of individuals battling these debilitating kidney diseases.
Read more from pharmabiz.com